Cara Therapeutics (CARA) Reiterated Overweight Ahead of Two Catalysts - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $38.00 price target on Cara Therapeutics (NASDAQ: CARA) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
